Clinical trials: Levosimendan
Ventricular Dysfunction, Left, Hip Fracture
Preoperative levosimendán and Hip Fracture
The purpose of this study is to evaluate whether preoperative optimization with levosimendan in heart failure patients undergoing hip fracture surgery improves haemodynamic and tissue perfusion parameters.
- Trial name
- OPL (NCT02972918)
- Testing
- Levosimendan
- Where
- Spain
- Volunteers
- 19 people
- Sponsor
- Hospital Universitario de Canarias
Coronary Artery Bypass Grafting, Mitral Valve Surgery
Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass
A study to evaluate levosimendan compared with placebo in reducing the composite event rate of all-cause death, perioperative MI, need for new dialysis, or use of mechanical assist (IABP, LVAD or ECMO) in subjects with reduced…
- Conditions
- Coronary Artery Bypass Grafting, Mitral Valve Surgery, Low Cardiac Output Syndrome
- Trial name
- LEVO-CTS (NCT02025621)
- Testing
- Levosimendan
- Where
- 60 sites in United States, Canada
- Volunteers
- 882 people
- Sponsor
- Tenax Therapeutics, Inc.
Low Cardiac Output Syndrome
Prophylactic Use of Levosimendan Versus Milrinone in Open Heart Surgery in Infants
Pediatric patients, especially infants undergoing open heart surgery have a predictable fall in cardiac index 6 to 18 hours after surgery, the so-called low cardiac output syndrome (LCOS).
- Trial name
- Levomil (NCT00549107)
- Testing
- Levosimendan, Milrinone
- Where
- Austria
- Volunteers
- 40 people
- Sponsor
- Ludwig Boltzmann Gesellschaft
Septic Shock, Cardiomyopathy
Effects of Levosimendan, Milrinone and Norepinephrine on Left and Right Ventricular Function in Septic Shock
The aim of this study is to investigate the effects milrinon and levosimandan on n heart function in septic cardiomyopathy and how norepinephrine affects the left and right ventricular function in patients with septick shock…
- Trial name
- SCLM (NCT02640846)
- Testing
- Norepinephrine, Milrinone, Levosimendan
- Where
- Sweden
- Volunteers
- 30 people
- Sponsor
- Sahlgrenska University Hospital
Congenital Cardiovascular Defects, Low Cardiac Output Syndrome
Levosimendan in Congenital Cardiac Surgery
Many pediatric patients undergoing cardiac surgery under cardiopulmonary bypass for repair of complex congenital malformations, require inotropic support for low cardiac output syndrome.
- Trial name
- NCT00695929
- Testing
- Levosimendan, Milrinone
- Where
- Belgium
- Volunteers
- 50 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Hypertension Pulmonary Secondary, Heart Failure, Right Sided
Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF
Phase 2 study to evaluate the efficacy and safety of intermittent levosimendan compared with placebo in hemodynamic improvement with exercise in PH-HFpEF subjects
- Conditions
- Hypertension Pulmonary Secondary, Heart Failure, Right Sided, Heart Failure With Normal Ejection Fraction
- Trial name
- HELP (NCT03541603)
- Testing
- Levosimendan
- Where
- 16 sites in United States
- Volunteers
- 44 people
- Sponsor
- Tenax Therapeutics, Inc.
Pulmonary Hypertension
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
This study will evaluate the efficacy of TNX-103 (oral levosimendan) compared with placebo in subjects with PH-HFpEF as measured by the change in 6-Minute Walk Distance (6 MWD; Day 1 to Week 12).
- Trial name
- LEVEL (NCT05983250)
- Testing
- TNX-103
- Where
- 42 sites in United States, Canada
- Volunteers
- 230 people
- Sponsor
- Tenax Therapeutics, Inc.
Cardiogenic Shock, Extracorporeal Membrane Oxygenation Complication
LEVOSIMENDAN to Facilitate Weaning From ECMO in Severe Cardiogenic Shock Patients
In the last decade, venoarterial extracorporeal membrane oxygenation (VA-ECMO) has become the first-line therapy in patients with refractory cardiogenic shock.
- Trial name
- LEVOECMO (NCT04728932)
- Testing
- Levosimendan
- Where
- 3 sites in France
- Volunteers
- 206 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Amyotrophic Lateral Sclerosis
Effects of Oral Levosimendan on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis (ALS): Open-Label Extension
This study provides an opportunity for subjects in the REFALS (3119002; NCT03505021) study to continue treatment with oral levosimendan.
- Trial name
- REFALS-ES (NCT03948178)
- Testing
- Levosimendan
- Where
- 79 sites in United States, Australia and 12 more
- Volunteers
- 227 people
- Sponsor
- Orion Corporation, Orion Pharma
Heart Valve Disease
The Effects of Levosimendan on Haemodynamics in Patients Undergoing Elective Aortic Valve Replacement (AVR)Together With Coronary Artery Bypass Grafting (CABG) Surgery
Patients undergoing aortic valve replacement (AVR) surgery with coronary artery bypass grafting (CABG) are at risk of left ventricular dysfunction.
- Trial name
- NCT01210976
- Testing
- levosimendan
- Where
- Finland
- Volunteers
- 24 people
- Sponsor
- Tampere University Hospital
Lung Transplant; Complications
Vasoactive-inotropic Support and Levosimendan Use After Lung Transplantation
Bilateral Lung transplantation (LUTX) is performed in selected patients with end-stage respiratory failure. During surgery, pulmonary arteries are sequentially cross-clamped.
- Trial name
- VASO_LUTX (NCT05702333)
- Testing
- Epinephrine Norepinephrine Dobutamine Dopamine Levosimendan
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Policlinico Hospital
Acute Decompensated Heart Failure
Interest of Levosimendan in Reducing Weaning Failures of ExtraCorporeal Life Support - ECLS
Extracorporeal life support (ECLS) is a circulatory cardio supplementation technique; it therefore makes it possible to compensate for a defective cardiac or cardio-respiratory function.
- Trial name
- Weanilevo (NCT04158674)
- Testing
- Levosimendan, Cernevit
- Where
- France
- Volunteers
- 82 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
ARDS, Human
A Clinical Study on Levosimendan Improvement of Prognosis of ARDS Patients by Optimizing Pulmonary Hemodynamics
The purpose of this study was to evaluate the curative effect of Levosimendan on ARDS patients through omni-directional and multi-angle objective quantitative indexes, and to study the responsiveness of ARDS with or without right…
- Trial name
- NCT04020003
- Testing
- Levosimendan
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shenzhen Second People's Hospital
Heart Failure New York Heart Association Class III, Heart Failure New York Heart Association Class IV
Levosimendan In Ambulatory Heart Failure Patients
The objective of the study is to determine the efficacy of repeated infusions of levosimendan in the group of outpatients with advanced systolic heart failure (HF).
- Conditions
- Heart Failure New York Heart Association Class III, Heart Failure New York Heart Association Class IV, Heart Failure, Systolic, Heart Failure With Reduced Ejection Fraction
- Trial name
- LEIA-HF (NCT04705337)
- Testing
- Levosimendan
- Where
- 14 sites in Poland
- Volunteers
- 70 people
- Sponsor
- Medical University of Bialystok
Sepsis, Septic Shock
Global Longitudinal Strain Assessment in Cardiogenic Shock During Sepsis
Cardiogenic shock is a condition of low cardiac output that represents the end of a progressive deterioration of cardiac function.
- Conditions
- Sepsis, Septic Shock, Cardiogenic Shock
- Trial name
- GLASSES-1 (NCT04141410)
- Testing
- Levosimendan, Echocardiography
- Where
- Italy
- Volunteers
- 35 people
- Sponsor
- Azienda USL Toscana Centro
Heart Failure, Hip Fracture
Preoperative Levosimendan and Heart Failure
The purpose of this study is to investigate the safety and efficacy of Levosimendan given preoperative to patients with heart failure undergoing noncardiac surgery.
- Trial name
- PELS (NCT01022983)
- Testing
- Levosimendan
- Where
- 4 sites in Norway, Sweden
- Sponsor
- Sykehuset i Vestfold HF
Cardiogenic Shock
Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock
Cardiogenic shock (CS) mortality remains high (40%). Despite their frequent use, few clinical outcome data are available to guide the initial selection of vasoactive drug therapies in patients with CS.
- Trial name
- LevoHeartShock (NCT04020263)
- Testing
- Levosimendan 2.5 MG/ML Injectable Solution
- Where
- 28 sites in France
- Volunteers
- 610 people
- Sponsor
- Pr Bruno LEVY
Mitral Valve Stenosis With Incompetence or Regurgitation
The Effects of Levosimendan During Mitral Valve Surgery
The effects of levosimendan on renal function in patients with low ejection fraction undergoing mitral valve surgery will be investigated in a prospective, double-blinded, randomized clinical trial using serum creatinine…
- Trial name
- NCT01969071
- Testing
- Levosimendan, Dobutamine
- Where
- Turkey (Türkiye)
- Volunteers
- 140 people
- Sponsor
- Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital
Mechanical Ventilation, Weaning Failure
Shorter Weaning From Invasive Ventilation With Levosimendan
Prolonged weaning from mechanical ventilation is a common and serious challenge in the ICU, associated with increased morbidity, mortality, and length of stay.
- Trial name
- WEANLESS (NCT07105202)
- Testing
- levosimendan, Soluvit, Standard care
- Where
- 8 sites in Netherlands
- Volunteers
- 250 people
- Sponsor
- Radboud University Medical Center
Levosimendan, Cardiac Surgery
Impact of Levosimendan Preconditioning on Critical Care and In-hospital Lengths of Stay After Cardiac Surgery With Bypass Surgery
Levosimendan, a drug with inotropic, vasodilatory and myocardial protective properties, has been proposed for the prevention and treatment of postoperative low cardiac output syndrome in cardiac surgery.
- Conditions
- Levosimendan, Cardiac Surgery, Cardiopulmonary Bypass
- Trial name
- LevoCCV (NCT05685537)
- Testing
- Levosimendan
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Central Hospital, Nancy, France